dactinomycin / Generic mfg. - LARVOL DELTA

RBM15 Contributes to Bladder Carcinoma Progression via m6A-dependent Stabilization of IFI6 mRNA. (PubMed, Appl Biochem Biotechnol) - "The N6-methyladenosine (m6A) modification sites on IFI6 were predicted by the sequence-based RNA adenosine methylation site predictor website and the combination of RBM15 was validated via RNA-binding proteins site prediction websites, methylated RNA immunoprecipitation, Actinomycin D, dual-luciferase reporter assay, and RNA binding protein immunoprecipitation assays. IFI6 was elevated in BLCA tissues and cells...RBM15, an m6A writer, directly bound IFI6 to stabilize its mRNA through m6A modification. Rescue experiments confirmed that IFI6 overexpression reversed RBM15 knockdown-mediated the suppression effect on BLCA cell proliferation and metastasis. Our study identifies that RBM15/IFI6 axis is a novel m6A-dependent pathway driving BLCA progression, offering a potential therapeutic target for BLCA."

Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urethral Cancer • RBM15

HNRNPC contributes to ccRCC progression by stabilizing AURKB mRNA in an m6A-dependent manner. (PubMed, Hum Cell) - "The role of HNRNPC in recognizing m6A modifications and regulating AURKB mRNA stability was validated through treatment with the methylation inhibitor STM-245, an actinomycin D stability assay, a dual-luciferase reporter assay, and RNA immunoprecipitation...In vivo experiments demonstrated that knockdown of either HNRNPC or AURKB significantly inhibited tumor growth and downregulated Ki-67 expression. In conclusion, HNRNPC contributes malignant progression of ccRCC, at least in part, by recognizing m6A modifications on AURKB mRNA and enhancing its stability, suggesting that the HNRNPC/AURKB axis may serve as a potential therapeutic target for ccRCC."

Journal • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor • AURKB • HNRNPC

PTBP1 promotes autophagy via the Slc22a17/Lcn2 axis to alleviate apoptosis in grafted islets (TTS 2026) - "Actinomycin D assays revealed that PTBP1 knockdown prolonged the half-life of Slc22a17 mRNA, indicating that PTBP1 destabilizes Slc22a17 transcripts... PTBP1 significantly reduces the stability of Slc22a17 mRNA in islet cells, modulates intracellular Lcn2 expression, thereby enhancing autophagy, attenuating apoptosis in transplanted β-cells, and ultimately improving the efficacy of islet transplantation."

Diabetes • Metabolic Disorders • PTBP1

FTO-mediated GPX4 m6A modification in ferroptosis-induced DNA damage and inflammatory response during acute lung injury. (PubMed, J Bioenerg Biomembr) - "GPX4 mRNA/protein stability and translation were analyzed using actinomycin D and cycloheximide...FTO exacerbates ALI by mediating m6A modification of GPX4 and downregulates its protein expression, thereby driving ferroptosis and DNA damage. Targeting the FTO-GPX4 axis may offer novel therapeutic strategies for ALI."

Journal • Acute Lung Injury • Genetic Disorders • Inflammation • Obesity • Respiratory Diseases • Targeted Protein Degradation • FTO • GPX4

RNA Labeling of Nucleolar Transcripts by 5-Ethynyl Uridine Click Chemistry. (PubMed, Methods Mol Biol) - "The method is straightforward, works across mammalian cells, and robustly reports nucleolar transcription under basal and stress conditions (heat shock; low-dose actinomycin D). Step-by-step instructions, reagent setup, image analysis metrics, troubleshooting, safety, and expected results are included so that researchers can reproducibly implement the assay."

Journal

A novel CAVIN1/GAS5 axis suppresses skin fibrosis through mitochondrial fission-mediated attenuation of the TGF-β/Smad pathway. (PubMed, Burns Trauma) - "Functional validation was performed by using primary keloid fibroblasts (KFs) with gain- and loss-of-function approaches, RNA immunoprecipitation sequencing (RIP-seq), and actinomycin D chase assays. Our study reports a novel CAVIN1/GAS5 axis that concurrently targets mitochondrial fission and the TGF-β/Smad pathway to suppress skin fibrosis. These findings not only reveal a previously unrecognized mechanistic link in keloid pathogenesis but also identify CAVIN1 as a promising therapeutic target, with vorinostat as a potential repurposable drug for treating fibrotic skin disorders."

Journal • Dermatology • Fibrosis • Immunology • GAS5 • TGFB1

METTL3 Promotes the Growth of Triple-Negative Breast Cancer Cells by Modulating Ferroptosis-Related Oxidative Stress via the ELF1/GPX4 Axis. (PubMed, Asia Pac J Clin Oncol) - "Bioinformatic analysis, MeRIP-PCR, and actinomycin D chase assays indicated that METTL3 was associated with increased N6-methyladenosine (m6A) enrichment, expression, and persistence of ELF1 mRNA...Crucially, the pro-proliferative and ferroptosis-associated effects of METTL3 overexpression were partially attenuated upon ELF1 knockdown or treatment with the ferroptosis inducer erastin. In conclusion, our findings suggest a novel METTL3/ELF1/GPX4 axis through which METTL3 promotes TNBC growth by regulating oxidative stress and ferroptosis-related markers, providing a basis for further investigation of this pathway in the context of TNBC biology and therapeutic development."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ACSL4 • ELF1 • GPX4 • METTL3

Mechanism of estrogen regulating the senescence and osteogenic differentiation of bone marrow mesenchymal stem cells via the METTL3/SATB2 axis. (PubMed, Pathol Res Pract) - "Estrogen regulates METTL3-mediated m6A modification to stabilize SATB2 mRNA via IGF2BP1, resulting in alleviated BMSC senescence and promoted OD. This finding provides a theoretical basis and potential intervention targets for BMSC-based anti-osteoporosis treatment strategies. The modulation of bone resorption and bone turnover, not addressed in this study, requires further validation."

Journal • Osteoporosis • Rheumatology • IGF2BP1 • METTL3

DYNLT1-TP53BP2 axis drives tamoxifen resistance in breast cancer by activating PI3K/Akt/mTOR signaling. (PubMed, Life Sci) - "These results reveal a new mechanism for PI3K/Akt/mTOR signaling activation in tamoxifen-resistant BC, driven by DYNLT1-mediated TP53BP2 degradation. This identifies DYNLT1 as a promising prognostic indicator and therapeutic intervention for tamoxifen resistance."

Journal • Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • DYNLT1

Actinomycin D in Combination With Low-Dose Cytarabine and Venetoclax in Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia (SOHO 2026) - "Seventy-four percent were previously exposed to intensive chemotherapy ± midostaurin, whereas 26% were treated with HMA± venetoclax. FLT3 comutations were identified, and additional gilteritinib was used in 63% of cases... The ACTIVE regimen demonstrates promising efficacy and tolerability in R/R NPM1m AML. Further evaluation in clinical trials is warranted. CR, complete remission, CRh: complete remission with partial hematologic recovery, CRi: complete remission with incomplete hematologic recovery, CRp: complete remission with incomplete platelet counts, MLFS: morphologic leukemia-free state."

Combination therapy • Acute Myelogenous Leukemia • Colorectal Cancer • Hematological Malignancies • Leukemia • Oncology • FLT3 • NPM1

CCL5 mRNA-enriched small extracellular vesicles from renal tubular epithelial cells enhance macrophage inflammatory responses in diabetic nephropathy. (PubMed, Inflamm Res) - "These findings suggest that TEC-derived sEV-associated Ccl5 mRNA may contribute to TEC-to-macrophage inflammatory communication in DN, with activated macrophages potentially propagating injury-related responses to glomerular cells."

Journal • Diabetes • Diabetic Nephropathy • Inflammation • Nephrology • Renal Disease • MYD88 • TLR4

Regulatory role of the circHIPK3/miR-125a-5p/NDUFA5 axis in diabetic retinopathy: combined analysis of single-cell and bulk transcriptomes. (PubMed, Am J Transl Res) - "In DR, circHIPK3 may sponge miR-125a-5p, relieving NDUFA5 inhibition and contributing to DR progression. NDUFA5 represents a potential therapeutic target for DR."

Journal • Diabetes • Diabetic Retinopathy • Oncology • Retinal Disorders • HIF1A • HIPK3 • IL6 • MIR125A • SDC4 • TNFA

Improving public cancer care by implementing precision medicine in Norway (clinicaltrialsregister.eu) - P1/2 | N=1000 | Recruiting | Sponsor: Oslo University Hospital HF | N=6000 ➔ 1000

Enrollment change • Oncology

m6A writer METTL14 restricts Mycobacterium tuberculosis infection by promoting TAX1BP1-mediated autophagy in macrophages. (PubMed, Immunobiology) - "Further, as validated by bioinformatic prediction, RIP assay and actinomycin D experiment, METTL14 directly bound to TAX1BP1 mRNA and enhanced its m6A modification, thereby stabilizing TAX1BP1 mRNA and upregulating its expression...Collectively, our findings demonstrate that METTL14, downregulated by Mtb infection, promotes macrophage autophagy and antibacterial activity via m6A-mediated stabilization of TAX1BP1. This METTL14-TAX1BP1-m6A pathway provides a novel therapeutic target for tuberculosis treatment."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • ALKBH5 • BECN1 • METTL14 • METTL3 • YTHDC1

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. (PubMed, J Clin Oncol) - "Conclusion The addition of VI to VAC did not improve EFS or OS for patients with intermediate-risk RMS. VAC/VI had less hematologic toxicity and a lower cumulative cyclophosphamide dose, making VAC/VI an alternative standard therapy for intermediate-risk RMS."

Clinical • Journal • Sarcoma

Upfront Allogeneic Stem Cell Transplantation With Individualized Venetoclax-Based Conditioning in MECOM-Rearranged Acute Myeloid Leukemia: A Single-Center Retrospective Study (SOHO 2026) - "Upfront allo-HSCT with individualized venetoclax-based conditioning, without requiring pretransplant CR, is feasible in MECOMr AML and yields high posttransplant CR/CRp and MRD negativity rates with low early mortality. Relapses and infectious complications remain the main drivers of mortality. Findings warrant cautious interpretation given the small retrospective cohort."

Retrospective data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • MECOM

Adult Atypical Teratoid/Rhabdoid tumor of the basisphenoid: a case report and multimodal treatment approach (EANO 2026) - "Starting on January 16, 2026, an intensified multimodal chemotherapy regimen was administered, including doxorubicin, followed by ICE (ifosfamide, carboplatin, etoposide) and subsequently VCA (vincristine, cyclophosphamide, dactinomycin). Despite the adoption of an aggressive multimodal therapeutic strategy, inoperable adult AT/RT remains a rare and highly aggressive malignancy, characterized by poor outcomes and a substantial unmet clinical need."

Case report • Clinical • Brain Cancer • CNS Tumor • Embryonal Tumor • Oncology • Rhabdoid Tumor • Sarcoma • SMARCB1

IGF2BP2 stabilizes SLC39A14 mRNA via m6A modification to promote ferroptosis in cerebral ischemia-reperfusion injury. (PubMed, Arch Biochem Biophys) - "We also quantified ferroptosis-related markers and detected m6A modification, RNA-protein interaction and mRNA stability via commercial kits, dot blot, MeRIP-qPCR, RIP-qPCR and actinomycin D assays...In vivo AAV-mediated SLC39A14 silencing reduced infarct volume, maintained BBB integrity and relieved neurological deficits. Collectively, IGF2BP2 facilitates CIRI development by driving neuronal ferroptosis through m6A-dependent regulation of SLC39A14 mRNA stability, which may serve as a promising therapeutic target for CIRI."

Journal • Cardiovascular • CNS Disorders • Hematological Disorders • Reperfusion Injury • IGF2BP2 • SLC39A1

Endothelin-1 drives COX-2 and prostaglandin E2 expression in osteoblasts through MAPK/AP-1 signaling during periodontal inflammation. (PubMed, J Dent Sci) - "Actinomycin D and cycloheximide significantly reduced ET-1-induced COX-2 expression and PGE2 release, indicating transcriptional and translational regulation...ET-1 also promoted c-Jun phosphorylation, nuclear accumulation, AP-1 binding activity, and COX-2 promoter transactivation, whereas AP-1 inhibition or c-Jun knockdown reduced COX-2 expression and downstream PGE2 production. ET-1 drives COX-2 expression and PGE2 release in osteoblasts through ETA/ETB dependent Gi/Gq, MAPK, and AP-1 signaling, supporting a potential role of ET-1 in osteoblast-associated inflammatory responses and inflammatory bone microenvironment changes under periodontal inflammatory conditions."

Journal • Inflammation • EDN1 • MAPK8 • PTGS2

Pathological transformation of rectal adenocarcinoma to choriocarcinoma in a male patient: A case report and review of the literature. (PubMed, Oncol Lett) - "The patient underwent two cycles of EMP/CO chemotherapy (etoposide, methotrexate, cisplatin/cyclophosphamide and vincristine); the standard treatment regimen for choriocarcinoma is EMA/CO (etoposide, methotrexate, actinomycin D/cyclophosphamide and vincristine), whereas in the present case, cisplatin was used in place of actinomycin D. Subsequently, β-hCG levels exhibited a marked decrease. Concurrently, post-treatment β-hCG level changes validated the therapeutic efficacy of EMP/CO. Furthermore, given the promising advances in antiangiogenic and immunotherapy research, these therapeutic approaches warrant further exploration alongside chemotherapy."

IO biomarker • Journal • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Rare Diseases • Rectal Adenocarcinoma • Solid Tumor

Molecular Analysis of miRNA Stability and Decay Dynamics by Northern Blot. (PubMed, Methods Mol Biol) - "This approach integrates transcriptional shutoff through actinomycin D treatment with advanced detection chemistries-specifically, EDC-mediated crosslinking and near-infrared fluorescent probe hybridization-to markedly enhance signal resolution and detection sensitivity, thereby facilitating precise determination of decay kinetics and reliable calculation of miRNA half-lives. Collectively, this method offers high specificity, enhanced sensitivity, and quantitative accuracy to investigate miRNA degradation dynamics at single-species resolution."

Biomarker • Journal

IGF2BP3 enhances paclitaxel resistance in bladder urothelial carcinoma by recognizing m6A-modified CENPA mRNA. (PubMed, Med Oncol) - "RNA stability was measured with actinomycin D treatment. IGF2BP3 promotes malignant phenotype and paclitaxel resistance in BUC by stabilizing CENPA mRNA. Targeting the IGF2BP3-CENPA axis may provide a novel therapeutic strategy to overcome chemoresistance in BUC."

Journal • Bladder Cancer • Oncology • Solid Tumor • Urothelial Cancer • CENPA • IGF2BP3

LncRNA OIP5-AS1 Promotes Glomerular Mesangial Cell Senescence by Interacting With ELAVL1 to Upregulate HMGB1. (PubMed, Cell Biochem Funct) - "To explore the underlying mechanism, RNA pull-down and RIP assays were performed to investigate the interactions among OIP5-AS1, ELAVL1, and HMGB1, while actinomycin D assays were used to evaluate HMGB1 mRNA stability...Rescue experiments further confirmed that ELAVL1 and HMGB1 mediated OIP5-AS1-induced GMC senescence. LncRNA OIP5-AS1 promotes GMC senescence by interacting with ELAVL1 to upregulate HMGB1."

Journal • Nephrology • Renal Disease • CDKN1A • ELAVL1 • HMGB1 • IL18 • IL1B • IL6 • TNFA

Comparing Efficacy and Safety of Biweekly Single-Dose Actinomycin D versus Multiday Methotrexate Therapy in Low-Risk Gestational Trophoblastic Neoplasia: A Prospective Multicentre Randomized Trial (SGO 2025) - No abstract available

Clinical • Late-breaking abstract • Gestational Trophoblastic Neoplasia • Oncology

Blastemal-Predominant Primary Extrarenal Nephroblastoma Associated with Lumbosacral Lipomeningocele in an Infant: A Case Report and Focused Review. (PubMed, Pediatr Dev Pathol) - "Normal bilateral kidneys, absence of teratomatous component, and negative metastatic work-up supported primary localized extrarenal disease. Complete excision was followed by vincristine/actinomycin-D-based chemotherapy; 6-month imaging showed no residual or recurrent lesion."

Journal • Embryonal Tumor • Nephrology • Oncology • Solid Tumor • Wilms Tumor • PAX8 • WT1